FMP

FMP

Enter

VRTX - Vertex Pharmace...

photo-url-https://images.financialmodelingprep.com/symbol/VRTX.png

Vertex Pharmaceuticals Incorporated

VRTX

NASDAQ

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

498.86 USD

-10.64 (-2.13%)

Historical Prices

From:

To:

498.24499500501502503504505505.5509:30 AM09:49 AM10:08 AM10:27 AM10:46 AM11:05 AM11:24 AM11:43 AM12:02 PM12:21 PM12:41 PM01:01 PM01:20 PM01:40 PM01:59 PM02:18 PM02:38 PM02:57 PM03:16 PM03:35 PM03:54 PM

About

ceo

Dr. Reshma Kewalramani FASN, M.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clin...

CIK

0000875320

ISIN

US92532F1003

CUSIP

92532F100

Address

50 Northern Avenue

Phone

617 341 6100

Country

US

Employee

6,100

IPO Date

Jul 24, 1991

Financial Statement

-4B-3B-2B-1B01B2B3B2023 Q42024 Q12024 Q22024 Q32024 Q4RevenueNet Income

Earnings

-15-12-9-6-30362023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q42025 Q1EPS Consensus

VRTX Financial Summary

CIK

0000875320

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

92532F100

ISIN

US92532F1003

Country

US

Price

498.86

Beta

0.51

Volume Avg.

1.5M

Market Cap

128.25B

Shares

-

52-Week

377.85-519.88

DCF

573.15

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-238.69

P/B

-

Website

https://www.vrtx.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest VRTX News

zacks.com

a day ago

Vertex Pharmaceuticals (VRTX) Outperforms Broader Market: Wh...

Vertex Pharmaceuticals (VRTX) reachead $509.47 at the closing of the latest trading day, reflecting a +1.19% change compared to its last close.

youtube.com

2 days ago

Final Trades: Berkshire Hathaway, Vertex Pharma, S&P Global ...

Final Trades are in! The Investment Committee reveals their top picks to close out the day—don't miss it!

zacks.com

2 days ago

What Analyst Projections for Key Metrics Reveal About Vertex...

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Vertex (VRTX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

seekingalpha.com

3 days ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.

seekingalpha.com

3 days ago

Baron Health Care Fund Q1 2025 Top Contributors And Detracto...

Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals saw increased investor confidence in its cystic fibrosis franchise and evolving pipeline, including promising non-opioid pain treatments and kidney disease drugs. UnitedHealth Group's shares gained as 2024 headwinds subsided, Medicare Advantage rates improved, and higher-margin Optum segments grew, in...

zacks.com

3 days ago

Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Card...

On VRTX's first-quarter earnings call, investors are likely to focus on the launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).

zacks.com

4 days ago

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Esti...

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

fool.com

4 days ago

My 5 Top Stocks to Buy Right Now in This Highly Volatile Mar...

Getting dizzy from the stock market's gyrations? Join the club.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep